On Jun. 6, 2022, Pfizer further strengthened its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its COVID-19 oral treatment, PAXLOVIDTM (nirmatrelvir [PF-07321332] tablets and ritonavir tablets).

The investment expanded the production of active pharmaceutical ingredient (API) and registered starting materials used in the manufacture of nirmatrelvir, a novel main protease (Mpro) inhibitor originating in Pfizer’s laboratories, which planned to create more than 250 additional high-skilled jobs at Pfizer’s Kalamazoo site.